Drug Profile
PF 232798
Alternative Names: PF-00232798; PF-232798Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Developer Pfizer; ViiV Healthcare
- Class Antivirals; Imidazoles; Piperidines
- Mechanism of Action CCR5 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 17 Jun 2015 Discontinued - Phase-I for HIV infections (In volunteers) in Singapore (PO)
- 17 Jun 2015 Discontinued - Phase-II for HIV infections in Germany (PO)
- 22 Dec 2010 Pfizer & ViiV Healthcare complete a phase I trial in Healthy volunteers in Singapore